Brief: Iovance Biotherapeutics Appoints Matthew Rosinack As Interim Principal Financial Officer
03/07/2025 21:10
July 3 (Reuters) - Iovance Biotherapeutics Inc IOVA.O: IOVANCE BIOTHERAPEUTICS INC - MATTHEW ROSINACK APPOINTED INTERIM PRINCIPAL FINANCIAL OFFICER - SEC FILING Further company coverage: IOVA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Iovance Biotherapeutics
See all newsBrief: Iovance Biotherapeutics Reports Inducement Grants
US RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Brief: Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., As Chief Medical Officer
Iovance hits two-year high after raising annual revenue forecast
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies